explore -WSS

explore

author：Wikipedia 2025-09-30 22:06:12 - browse：56328

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Popular nasal decongestant doesn't actually relieve congestion

leisure time

focus

WSS

Our daughter's deadly disease: trisomy 18. We wanted to protect her

New weight loss drugs vying to be the next Wegovy or Mounjaro

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

What to make of Biden’s latest efforts on cancer research

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

FDA official pushes for dedicated emerging pathogens team

focus

explore

entertainment

In Memoriam: Notable people who died in 2023

Why an extreme heat and wildfire smoke combination can be so dangerous

BioMarin wins approval for gene therapy to treat hemophilia A

Caitlin Bernard's story shows physicians can't shy from advocacy

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

White House launches permanent pandemic office

Tori Bowie and the unacceptable rates of Black maternal death

Food makers to regulators: Ultra

BioMarin wins approval for gene therapy to treat hemophilia A

White House touts steps to stem shortages of cancer treatments

hotspot

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Why an extreme heat and wildfire smoke combination can be so dangerous

How medical schools plan to diversify without affirmative action

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Popular nasal decongestant doesn't actually relieve congestion

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

focus

leisure time

focus

entertainment